Scientists from Korea have developed a new biosensor that uses fluorescence resonance energy transfer (FRET) to detect DNA double-strand breaks in living specimens in real time. This biosensor has the potential to aid the development of new treatments for DNA damage-related diseases by revealing how our… Read More
News round-up for 13-17 March by DDW Digital Content Editor Diana Spencer. In the news this week we have covered a number of early-stage studies that could lead to potentially huge breakthroughs in the treatment of metastatic breast cancer, long Covid, bacterial diseases, bone cancer, and autoimmune… Read More
Ellipses Pharma, a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, has been granted Orphan Drug Designation (ODD) by the FDA for EP0042, a dual FLT-3 and Aurora kinase inhibitor, for the treatment of acute myeloid leukaemia… Read More
Researchers at the University of East Anglia have developed a new drug that works against all of the main types of primary bone cancer. The study shows how a breakthrough drug called CADD522 blocks a gene associated with driving the cancer’s spread in mice implanted with… Read More
Scientists have discovered why breast cancer cells that have spread to the lungs may ‘wake up’ following years of sleep – forming incurable secondary tumours. Patients with oestrogen receptor positive (ER+) breast cancer – the most common type – have a continued risk of their cancer… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Perhaps most interestingly this week, after previous caution over in vivo… Read More
News round-up for 6-10 March by DDW Digital Content Editor Diana Spencer. Perhaps most interestingly this week, after previous caution over in vivo gene therapy trials, the FDA has given the go ahead to Intellia Therapeutics to study NTLA-2002 in hereditary angioedema (HAE). There have been several… Read More
Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. The collaboration focuses on the development of two investigational antibody candidates, UCB6114 and UCB4594, by bringing together the oncology-focused translational research and clinical… Read More
Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2. Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with… Read More
Dr John Ballantyne, co-founder of Aldevron, has invested $3 million in CureLab Oncology and CureLab Veterinary. The two sister companies have developed an anti-cancer and anti-inflammatory drug that was contract-manufactured by Aldevron at the time Dr Ballantyne served there as chief scientific officer. Both CureLab Oncology and CureLab Veterinary are… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As well as providing extensive coverage of the … Read More
News round-up for 27 February – 3 March by DDW Digital Content Editor Diana Spencer. As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day, DDW has also reported on a… Read More
SiSaf is to collaborate with the University of Leipzig, Germany, to develop targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer. The collaboration will combine SiSaf’s expertise in RNA delivery using its Bio-Courier silicon-stabilised hybrid lipid nanoparticles (sshLNPs) and… Read More
CAR-T cell therapy is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer. The study authors, who work at Karolinska Institutet, hope that the discovery will pave the way for a clinical trial… Read More
Cancer Research Horizons and Singapore’s Experimental Drug Development Centre (EDDC) have announced a five-year strategic partnership to accelerate the translation of cancer research into improved treatments for cancer patients. The international alliance will focus on leveraging the complementary capabilities, platforms and technologies from both partners, to accelerate… Read More
DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in precision and targeted treatments for cancer and asked what advances the future might bring. The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview… Read More
